ArticleBMC oral health2024
Effect of oxyresveratrol under in vitro lipopolysaccharide-induced periodontitis environment.
Article in BMC oral health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- In vitro biocompatibility evaluation of three-dimensionally printed resin crowns for primary molars.Odontology · 2026Article
- A scientometric study on the characteristics of herbal medicine and identification of herbaceous agents for treatment of periodontal diseases.Journal of dental sciences · 2026Article
- Progesterone-induced activation of progesterone receptor alleviates alveolar bone resorption and inflammatory response in periodontitis.Clinical oral investigations · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOxyresveratrol is the main constituent of mulberries and has many bioactive properties beneficial to human health. The purpose of this study was to assess the anti-inflammatory effects of oxyresveratrol on in vitro periodontitis model.
methodsHuman periodontal ligament cells were treated with oxyresveratrol (0, 10, and 20 µg/mL) for 72 h. Cell viability and flow cytometry assays were performed. To investigate anti-inflammatory effect of oxyresveratrol on periodontal inflammation, nitric oxide production under lipopolysaccharide stimulation was assessed. Next, expression of biomarkers associated periodontal inflammation was evaluated. Scratch wound assay was performed to evaluate cell migration/proliferation potential of oxyresveratrol under lipopolysaccharide stimulation.
resultsPeriodontal ligament cell toxicity was not observed in oxyresveratrol treatment. Oxyresveratrol treatment significantly inhibited nitric oxide production and reduced MMP-2, MMP-9, TNF-α, IL-6, and IL-8 expressions after lipopolysaccharide stimulation. Regarding cell migration/proliferation, open wound area in oxyresveratrol (33.28 ± 6.80%) was the lowest (p < 0.05).
conclusionsWithin the limits of this study, oxyresveratrol inhibited lipopolysaccharide-induced inflammation in periodontal ligament cells and promoted periodontal ligament cell migration/proliferation. These findings suggest that oxyresveratrol could be valuable for the management of periodontal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.